IP Library › Granted Patent US 10,556,966
Granted Patent B2
US 10,556,966 · App. 16/170,819 · Granted Feb 11, 2020

Anti-HER2 antibodies and immunoconjugates

Inventors: Xiaocheng Chen (Burlingame, CA); Mark Dennis (San Carlos, CA); Jagath Reddy Junutula (Fremont, CA); Gail Lewis Phillips (San Carlos, CA); Thomas Harden Pillow (San Francisco, CA); Mark X. Sliwkowski (San Carlos, CA)
Assignee: Genentech, Inc.
C07K16/32A61K31/5517A61K31/675A61K31/704A61K39/3955A61K47/68A61K47/6809A61K47/6849A61K47/6855A61K47/6863A61K49/00C07K16/2863C07K16/3015G01N33/57415G01N33/57446G01N33/57492C07K2317/24C07K2317/34C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/73C07K2317/92G01N2333/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,556,966
App. No.
16/170,819
Granted
Feb 11, 2020
Kind
B2
Abstract

The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

Claims (46)

1. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:16; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

2. A host cell comprising the nucleic acid of claim 1 .

3. A method of producing an antibody comprising culturing the host cell of claim 2 so that the antibody is produced.

4. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:20; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

5. A host cell comprising the nucleic acid of claim 4 .

6. A method of producing an antibody comprising culturing the host cell of claim 5 so that the antibody is produced.

7. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:21; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

8. A host cell comprising the nucleic acid of claim 7 .

9. A method of producing an antibody comprising culturing the host cell of claim 8 so that the antibody is produced.

10. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:8; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:22; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

11. A host cell comprising the nucleic acid of claim 10 .

12. A method of producing an antibody comprising culturing the host cell of claim 11 so that the antibody is produced.

13. The nucleic acid of claim 1 , wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

14. The nucleic acid of claim 1 , wherein the antibody comprises a κ light chain.

15. The nucleic acid of claim 1 , wherein the anti-HER2 antibody comprises a heavy chain comprising at least one mutation in the heavy chain constant region selected from A118C and S400C.

16. The nucleic acid of claim 1 , wherein the anti-HER2 antibody comprises a light chain comprising at least one mutation in the light chain constant region selected from K149C and V205C.

17. The nucleic acid of claim 4 , wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

18. The nucleic acid of claim 4 , wherein the antibody comprises a κ light chain.

19. The nucleic acid of claim 4 , wherein the anti-HER2 antibody comprises a heavy chain comprising at least one mutation in the heavy chain constant region selected from A118C and S400C.

20. The nucleic acid of claim 4 , wherein the anti-HER2 antibody comprises a light chain comprising at least one mutation in the light chain constant region selected from K149C and V205C.

21. The nucleic acid of claim 7 , wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

22. The nucleic acid of claim 7 , wherein the antibody comprises a κ light chain.

23. The nucleic acid of claim 7 , wherein the anti-HER2 antibody comprises a heavy chain comprising at least one mutation in the heavy chain constant region selected from A118C and S400C.

24. The nucleic acid of claim 7 , wherein the anti-HER2 antibody comprises a light chain comprising at least one mutation in the light chain constant region selected from K149C and V205C.

25. The nucleic acid of claim 10 , wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

26. The nucleic acid of claim 10 , wherein the antibody comprises a κ light chain.

27. The nucleic acid of claim 10 , wherein the anti-HER2 antibody comprises a heavy chain comprising at least one mutation in the heavy chain constant region selected from A118C and S400C.

28. The nucleic acid of claim 10 , wherein the anti-HER2 antibody comprises a light chain comprising at least one mutation in the light chain constant region selected from K149C and V205C.

29. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises:

(i) a heavy chain variable region comprising the sequence of SEQ ID NO: 11 and a light chain variable region comprising the sequence of SEQ ID NO: 10; or

(ii) a heavy chain comprising the sequence of SEQ ID NO: 19 or SEQ ID NO: 24 and a light chain comprising the sequence of SEQ ID NO: 18 or SEQ ID NO: 23.

30. A host cell comprising the nucleic acid of claim 29 .

31. A method of producing an antibody comprising culturing the host cell of claim 30 so that the antibody is produced.

32. The nucleic acid of claim 29 , wherein the antibody is an IgG1, IgG2a or IgG2b antibody.

33. The nucleic acid of claim 29 , wherein the antibody comprises a κ light chain.

34. The nucleic acid of claim 29 , wherein the anti-HER2 antibody comprises a heavy chain comprising at least one mutation in the heavy chain constant region selected from A118C and S400C.

35. The nucleic acid of claim 29 , wherein the anti-HER2 antibody comprises a light chain comprising at least one mutation in the light chain constant region selected from K149C and V205C.

36. The nucleic acid of claim 29 , wherein the anti-HER2 antibody comprises a heavy chain comprising the sequence of SEQ ID NO: 19 and a light chain comprising the sequence of SEQ ID NO: 18.

37. A host cell comprising the nucleic acid of claim 36 .

38. A method of producing an antibody comprising culturing the host cell of claim 37 so that the antibody is produced.

39. The nucleic acid of claim 29 , wherein the anti-HER2 antibody comprises a heavy chain comprising the sequence of SEQ ID NO: 24 and a light chain comprising the sequence of SEQ ID NO: 18.

40. A host cell comprising the nucleic acid of claim 39 .

41. A method of producing an antibody comprising culturing the host cell of claim 40 so that the antibody is produced.

42. The nucleic acid of claim 29 , wherein the anti-HER2 antibody comprises a heavy chain comprising the sequence of SEQ ID NO: 19 and a light chain comprising the sequence of SEQ ID NO: 23.

43. A host cell comprising the nucleic acid of claim 42 .

44. A method of producing an antibody comprising culturing the host cell of claim 43 so that the antibody is produced.

Continuity (4)
Division 15296454 · Oct 18, 2016
Division 14851001 · Sep 11, 2015
Provisional Application 62049594 · Sep 12, 2014
Related Publication 20190177429A1 · Jun 13, 2019
Cited By (1)
US 12,492,263